Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — Q3 FY24 Earnings Presentation
33 slides from Gufic Biosciences's earnings presentation, Feb 14, 2024
Slide 1: Exchange filing cover letter for investor presentation
22/LG/SE/FEB/2024/GBSL February 14, 2024 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Investor Present
Slide 2: Delivering Care & Cure - Investor Presentation February 2024
Delivering Care & Cure Investor Presentation February 2024
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by and is the sole responsibility of Gufic Biosc iences Limited (the “ Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions . This presentation does not constitute or form part of any offer or invitation
Slide 4: Q3 FY24 Business & Financial Highlights
Q3 FY24 Business & Financial Highlights
Slide 5: Q3 FY24 Business Highlights
Q3 FY24 Business Highlights Indore Capex Update: • State-of-the-Art Manufacturing Facility for Injectables: • Initiated the construction of the manufacturing facility for injectable products in December 2021. • This state-of-the-art facility is equipped with advanced automation technology and is ful
Slide 6: Q3 FY24 Business Highlights
Q3 FY24 Business Highlights Critical Care Division Market Penetration and Preference: Domestic Business Breakup • Gufic's Critical Care brands have penetrated over 1500 hospitals and are recognized as the preferred choice by the medical fraternity. Critical Care Division • Brands such as Guficap, Mi
Slide 7: Q3 FY24 Business Highlights
Q3 FY24 Business Highlights Ferticare Division Brand Recognition and Engagement: Innovative Product Development: • Introduced the theme "Think Critical Care, Think Gufic" to • Development of Supergraf, an ultra-purified HMG formulation. enhance brand recognition and association. • Represents a signi
Slide 8: Q3 FY24 Business Highlights
Q3 FY24 Business Highlights Scientific Image Building and Market Expansion: Spark, Stellar & Healthcare Division: • Aiming to establish itself as a science-driven company while expanding Strong Growth in Spark Division: market presence through strategic initiatives. • Witnessed robust growth with su
Slide 9: Q3 FY24 Business Highlights
Q3 FY24 Business Highlights Aestherderm Division: • Aesthaderm achieved a significant milestone by becoming the first Indian Dermatology Company to host FACE OFF, a hands-on Cadaver and injectables workshop in India. This event, conducted in collaboration with International Speaker Dr. Niamh Corduff
Slide 10: Q3 FY24 Business Highlights
Q3 FY24 Business Highlights Arisia, The Center of Excellence • Elevating Aesthetic Excellence in Mumbai: Introducing Arisia, our Center of Excellence in Mumbai—a cutting-edge aesthetic clinic and training center that redefines the benchmarks for excellence in aesthetic care. Arisia is meticulously d
Slide 11: Research & Development
Research & Development Update on R&D Update on Selvax • Peptides R&D: Paving the Way for In-house Critical • Positive Results from Mouse Studies: API Manufacturing: Our foray into peptides research and development aligns seamlessly with our broader • Selvax conducted comprehensive studies in mice us
Slide 12: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 13: Profit & Loss Statement
Profit & Loss Statement Pa r t i c u l a rs ( i n R s . C r o re) Q3 FY24 Q3 FY23 9M FY24 9M FY23 To ta l Rev e n u e 201.8 177.5 611.7 517.6 E B I T DA 36.9 34.2 112.94 101.1 E B I T DA M a r g i n % 18.3% 19.3% 18.5% 19.5% P ro f i t b efo re Ta x 29.6 27.2 88.6 82.8 P BT M a r g i n s % 14.7% 15.
Slide 14: Company Overview
Company Overview
Slide 15: About Gufic Biosciences
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas BUSINESS STRUCT
Slide 16: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Amphotericin B and Depot Injections Natura
Slide 17: Upcoming World Class Manufacturing Infrastructure
Upcoming World Class Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON CAPEX Indore Lyophilized/Powder Injectables Dedicated facility for Penem Received Drug Manufacturing License from FDA, Madhya Facility Carbapenems (Lyophilized / Dry Pradesh Capability to cater to regulated
Slide 18: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 19: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s Field Force: 250 Field Force: >150 Field Force: >180 200+ Therapy Areas: Antibacterial, Therapy Areas: Hormones, Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 20: Expanding Creditability in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 21: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 22: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 23: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 24: Extensive Sales, Distribution & IT Infrastructure in India
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure Retail coverage of more than 23 Carrying & Forwarding (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 25: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 26: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 27: Historical Financials
Historical Financials
Slide 28: Historical Financials
Historical Financials Total Revenue EBITDA & EBITDA Margin Profit After Tax & PAT Margin 15.8% 15.1% 17.8% 19.3% 19.8% 7.4% 5.9% 9.0% 12.3% 11.5% 782 693 151 96 137 491 80 385 360 88 44 57 58 27 23 2019 2020 2021 FY22* FY23 2019 2020 2021 FY22* FY23 2019 2020 2021 FY22 FY23 CAGR 18% CAGR 31% CAGR 38
Slide 29: Historical Financials
Historical Financials Particulars (Rs. Crs.) FY23 FY22 FY21 FY20 FY19 FY18 Revenue from Operations 693.2 782.3 491.4 384.6 359.5 311.6 EBITDA 137.2 151.1 87.7 57.9 56.7 41.6 EBITDA Margin % 19.8% 19.3% 17.8% 15.1% 15.8% 13.4% Profit before Tax 106.7 126.8 57.7 30.1 40.2 30.0 PBT Margin % 15.4% 16.2%
Slide 30: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 9.7 9.7 9.7 9.7 9.7 Other Equity 338.1 259.4 163.7 119.6 102.8 Total Equity 347.8 269.1 173.4 129.3 112.5 Non-Current Liabilities Financial Liabilities i. Borrowing
Slide 31: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 126.8 105.5 93.8 72.7 70.3 Intangible assets 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 169.6 40.9 13.4 30.6 9.6 Right of use assets 32.1 9.1 5.8 9.3 0.0 Financia
Slide 32: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 106.7 126.9 57.7 30.1 35.3 Adjustments for: Non - Cash Items / Other Investment or 29.6 23.2 30.8 24.7 13.4 Financial Items Operating profit before working capital changes 136.4 150.0 88.5 54.8 48.7 C
Slide 33: Thank You
THANK YOU Company: Gufic Biosciences Limited CIN: L24100MH1984PLC033519 Mr. Avik Das – Investor Relations avik.das@guficbio.com Tel: +91 22 67261000